Question explored with the scientific record
Conversation so far
Answered on this page ↓
how to cure high cholesterol
The question asks how to cure high cholesterol, and the evidence supplied mostly tests whether statins reduce cardiovascular events in people who already have heart disease. That is a different question.
The evidence does not contain a single study comparing a cholesterol-lowering intervention to a true untreated group in healthy people with high cholesterol and measuring whether it prolongs life. Every trial here enrolled patients with existing disease—prior heart attack, stroke, diabetes, or documented coronary artery disease—and compared a drug to placebo or to a weaker drug [1, 4, 7]. The meta-analysis of 100,610 patients on added ezetimibe or PCSK9 inhibitors showed reduced cardiovascular events but no significant reduction in all-cause mortality [1]. The Heart Protection Study with 20,536 high-risk patients showed reduced vascular deaths but the absolute all-cause mortality reduction was about 1% over five years, and 32% of the placebo group was taking a non-study statin by year five, which blurs the comparison [7].
The 2020 BMI meta-analysis of 266,148 patients found that the cardiovascular mortality benefit of intensive LDL lowering disappeared in obese patients (HR 0.96, CI 0.68–1.33) and was strongest in those with BMI under 25 (HR 0.57, CI 0.37–0.86) [2]. That tells you the benefit is not uniform. The 1999 meta-analysis of 14 trials found a 24% all-cause mortality reduction with statins versus placebo, but every trial recruited people with existing vascular disease or very high risk [4].
| Population | All-cause mortality effect | Source |
|---|---|---|
| High-risk patients, simvastatin vs placebo | RR 0.87 (0.80–0.94) | [7] |
| CAD patients, intensified therapy vs statin alone | OR 0.94 (0.85–1.05)* | [1] |
| Obese patients (BMI ≥30), intensive LDL lowering | HR for CV death 0.96 (0.68–1.33) | [2] |
*not statistically significant
My call: for a healthy person with isolated high cholesterol and no existing heart disease, the evidence here does not prove that any drug prolongs life. The trials that show mortality benefit all started with people who already had disease. Absent that, the question of "cure" is not answered by this retrieval. Confidence: low that any intervention in the evidence cures high cholesterol in the way a patient means it—the evidence tests secondary prevention, not treatment of a lab value.
Sources used 20
-
P5015Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events: A meta-analysis
In a meta-analysis of 9 randomized controlled trials including 100,610 patients, intensified lipid-lowering therapy with ezetimibe or PCSK9 inhibitors added to statins reduced cardiovascular events by 18%, myocardial infarction by 16%, and ischemic stroke by 23%, but did not sig…
DOI: 10.1093/eurheartj/ehz746.0193 -
Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy
A comprehensive meta-analysis of 29 randomized trials (266,148 patients) shows that baseline body mass index (BMI) modulates the cardiovascular benefit of intensive LDL-C lowering therapy, with the greatest reductions in cardiovascular and all-cause mortality observed in individ…
DOI: 10.1016/j.amjcard.2019.12.006 -
Primary Prevention of Coronary Artery Disease
This article discusses the long-term outcomes of the West of Scotland Coronary Prevention Study (WOSCOPS) and the implications for early statin therapy and LDL cholesterol targets in the primary prevention of coronary heart disease, including supporting evidence from PCSK9-relat…
DOI: 10.1056/nejme078183 -
Clinical Outcomes in Statin Treatment Trials
A comprehensive meta-analysis of randomized statin trials (≥1 year) showing that statin therapy reduces all-cause mortality and major cardiovascular events versus placebo, with variation in effect across statin types and study designs and notable overall applicability across pri…
DOI: 10.1001/archinte.159.15.1793 -
The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease
The Jupiter study demonstrated that rosuvastatin significantly reduces cardiovascular events and all-cause mortality in apparently healthy individuals with elevated C-reactive protein levels, suggesting the need for statin therapy in this population.
DOI: 10.1177/1753944709337056 -
Omega-3 fatty acids have little or no cardiovascular protection: An interventional study
Omega-3 fatty acid supplementation (EPA/DHA) for six months did not provide cardiovascular protection compared with atorvastatin in adults at risk of cardiovascular disease, with statin therapy yielding greater improvements in lipid and blood pressure parameters.
DOI: 10.54517/ccr.v3i2.2116 -
The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]
A large, randomized placebo-controlled trial (Heart Protection Study) in 20,536 high-risk UK adults shows that lowering LDL cholesterol with simvastatin 40 mg daily for about 5 years reduces vascular mortality by ~17% and major vascular events by ~25% without increasing non-vasc…
DOI: 10.1186/1741-7015-3-6 -
A peri‐operative statin update for non‐cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non‐surgical) patients
This review synthesizes evidence on statin therapy for peri-operative use, concluding that stable coronary artery disease patients require 4-6 weeks of therapy with LDL-C reduction as the key target, while patients experiencing acute coronary syndromes need early high-dose stati…
DOI: 10.1111/j.1365-2044.2007.05264.x -
Statin therapy in acute cardioembolic stroke with no guidance-based indication
Starting statin therapy during hospitalization for acute cardioembolic stroke in patients without guideline-based statin indications significantly reduced major vascular events (adjusted HR 0.39, 95% CI 0.31–0.48), vascular death (HR 0.28, 0.21–0.36), and all-cause death (HR 0.5…
DOI: 10.1212/wnl.0000000000009397 -
Interleukin-1 inhibition and ischaemic stroke: has the time for a major outcomes trial arrived?
The study demonstrates that inflammation inhibition through canakinumab significantly reduces cardiovascular event rates in post-myocardial infarction patients with residual inflammatory risk, independent of lipid-lowering effects.
DOI: 10.1093/eurheartj/ehy360 -
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
The ALERT trial investigated the effects of fluvastatin on cardiac and renal endpoints in 2102 renal transplant recipients, finding a significant reduction in cardiac deaths and non-fatal myocardial infarctions, but no overall reduction in major adverse cardiac events.
DOI: 10.1016/S0140-6736(03)13638-0 -
High-risk elderly patients PROSPER from cholesterol-lowering therapy
The PROSPER trial demonstrated that pravastatin significantly reduces the risk of coronary events in high-risk elderly individuals, although the proportional reduction was smaller than anticipated compared to previous studies.
DOI: 10.1016/s0140-6736(02)11650-3 -
Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
The IMPROVE-IT trial demonstrated that adding ezetimibe to statin therapy significantly reduces cardiovascular events in both women and men after acute coronary syndrome, with a favorable safety profile.
DOI: 10.1161/JAHA.117.006901 -
Effect of niacin on atherosclerotic cardiovascular disease
Niacin lowers major cardiovascular events in several large trials, with monotherapy showing long-term mortality benefit and combination regimens reducing events, though mortality results vary and side effects are common.
DOI: 10.1016/s0002-9149(98)00767-x -
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study
IDEAL is a multicenter randomized PROBE-design trial comparing high-intensity atorvastatin (80 mg) versus moderate-intensity simvastatin (20 mg, titrated to 40 mg) in patients with prior myocardial infarction to determine whether a larger LDL cholesterol reduction (~55%) yields …
DOI: 10.1016/j.amjcard.2004.06.003 -
Atorvastatin
A comprehensive review of atorvastatin’s pharmacology, safety, and clinical trial evidence for LDL lowering and potential cardiovascular benefits across diverse populations, highlighting notable LDL reductions, trial outcomes, and ongoing uncertainties regarding hard endpoint be…
DOI: 10.1517/14656566.2.5.819 -
Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients
A post-hoc analysis of the COURAGE trial shows that in stable ischemic heart disease patients treated with aggressive medical therapy, low HDL cholesterol remains associated with higher long-term cardiovascular risk, and this risk persists even when LDL cholesterol is aggressive…
DOI: 10.1016/j.jacc.2013.07.051 -
Statin dose titration patterns and subsequent major cardiovascular events in very high-risk patients: estimates from Swedish population-based registry data
Early up-titration to high-intensity statins within 12 weeks was associated with a statistically significant lower risk of major cardiovascular events within 2 years compared to no up-titration in very high-risk patients, but few patients titrated in real-world practice.
DOI: 10.1093/ehjqcco/qcaa023 -
Inhibiting Translation One Protein at a Time
A commentary describing how a small molecule (PF-06446846) can selectively stall ribosome elongation to inhibit translation of PCSK9, lowering LDL cholesterol in animal models, and highlighting a potential general strategy to target undruggable proteins.
DOI: 10.1016/j.tibs.2017.04.008 -
Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction
This paper reviews the efficacy and mechanisms of action of alirocumab, a monoclonal antibody targeting PCSK9, in reducing LDL cholesterol levels and its potential implications for cardiovascular disease management.
DOI: 10.1586/14779072.2014.954551